A Case of Fulminant Immune-Related Enterocolitis During Immune Checkpoint Inhibitor Therapy for Metastatic Renal Cell Carcinoma.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
ICIs therapy for mRCC and was urgently hospitalized because of worsening diarrhea
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Persistent diarrhea during ICIs therapy requires prompt evaluation and specialist consultation, even when symptoms appear mild, as they may signal immune-related enterocolitis. Clinicians should also remain vigilant for infectious complications, which can exacerbate the severity of immune-related enterocolitis and lead to life-threatening outcomes.
OpenAlex 토픽 ·
Multiple and Secondary Primary Cancers
Renal cell carcinoma treatment
Cancer Immunotherapy and Biomarkers
[INTRODUCTION] Combination therapy with immune checkpoint inhibitors (ICIs) has become a standard treatment for metastatic renal cell carcinoma (mRCC).
APA
Kasumi Kanai, Takayuki Sumiyoshi, et al. (2026). A Case of Fulminant Immune-Related Enterocolitis During Immune Checkpoint Inhibitor Therapy for Metastatic Renal Cell Carcinoma.. IJU case reports, 9(3), e70181. https://doi.org/10.1002/iju5.70181
MLA
Kasumi Kanai, et al.. "A Case of Fulminant Immune-Related Enterocolitis During Immune Checkpoint Inhibitor Therapy for Metastatic Renal Cell Carcinoma.." IJU case reports, vol. 9, no. 3, 2026, pp. e70181.
PMID
42005992
Abstract
[INTRODUCTION] Combination therapy with immune checkpoint inhibitors (ICIs) has become a standard treatment for metastatic renal cell carcinoma (mRCC). However, ICIs may also cause immune-related adverse events. We report a case of mRCC that developed fulminant immune-related enterocolitis.
[CASE PRESENTATION] A 79-year-old man received ICIs therapy for mRCC and was urgently hospitalized because of worsening diarrhea. Despite the initiation of steroid therapy, circumferential intestinal necrosis developed, necessitating subtotal colectomy. The patient subsequently developed cytomegalovirus- and Epstein-Barr virus-associated enterocolitis and died from extensive intestinal necrosis caused by severe thrombosis secondary to disseminated intravascular coagulation.
[CONCLUSION] Persistent diarrhea during ICIs therapy requires prompt evaluation and specialist consultation, even when symptoms appear mild, as they may signal immune-related enterocolitis. Clinicians should also remain vigilant for infectious complications, which can exacerbate the severity of immune-related enterocolitis and lead to life-threatening outcomes.
[CASE PRESENTATION] A 79-year-old man received ICIs therapy for mRCC and was urgently hospitalized because of worsening diarrhea. Despite the initiation of steroid therapy, circumferential intestinal necrosis developed, necessitating subtotal colectomy. The patient subsequently developed cytomegalovirus- and Epstein-Barr virus-associated enterocolitis and died from extensive intestinal necrosis caused by severe thrombosis secondary to disseminated intravascular coagulation.
[CONCLUSION] Persistent diarrhea during ICIs therapy requires prompt evaluation and specialist consultation, even when symptoms appear mild, as they may signal immune-related enterocolitis. Clinicians should also remain vigilant for infectious complications, which can exacerbate the severity of immune-related enterocolitis and lead to life-threatening outcomes.